Russell Investments Group
SYRS

Russell Investments Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Russell Investments Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-750
Closed -$1.61K – 3815
2024
Q3 		$1.61K Hold
750
– – ﹤0.01% 3413
2024
Q2 		$3.87K Hold
750
– – ﹤0.01% 3267
2024
Q1 		$4.01K Hold
750
– – ﹤0.01% 2973
2023
Q4 		$5.84K Hold
750
– – ﹤0.01% 2892
2023
Q3 		$2.96K Hold
750
– – ﹤0.01% 3214
2023
Q2 		$2.36K Hold
750
– – ﹤0.01% 3213
2023
Q1 		$2K Hold
750
– – ﹤0.01% 3007
2022
Q4 		$2.69K Hold
750
– – ﹤0.01% 2879
2022
Q3 		$4K Hold
750
– – ﹤0.01% 2884
2022
Q2 		$7K Sell
750
-154
-17% -$1.44K ﹤0.01% 2854
2022
Q1 		$9K Sell
904
-51
-5% -$912 ﹤0.01% 2714
2021
Q4 		$30K Sell
955
-74
-7% -$3K ﹤0.01% 2931
2021
Q3 		$45K Sell
1,029
-1,005
-49% -$49.1K ﹤0.01% 2952
2021
Q2 		$109K Sell
2,034
-2,407
-54% -$142K ﹤0.01% 3040
2021
Q1 		$331K Buy
4,441
+4,231
+2,015% +$440K ﹤0.01% 2676
2020
Q4 		$22K Sell
210
-1,665
-89% -$152K ﹤0.01% 2977
2020
Q3 		$165K Buy
1,875
+979
+109% +$111K ﹤0.01% 2844
2020
Q2 		$95K Buy
896
+685
+325% +$61.5K ﹤0.01% 2894
2020
Q1 		$12K Buy
+211
New +$14.3K ﹤0.01% 2980
2018
Q1 		– Sell
-3,342
Closed -$330K – 3022
2017
Q4 		$330K Buy
3,342
+2,439
+270% +$328K ﹤0.01% 2558
2017
Q3 		$133K Buy
+903
New +$170K ﹤0.01% 2736

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Russell Investments Group's SYRS Position: Q4 2024 in Review

Russell Investments Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 750 shares — an estimated $1.61K sold.

Russell Investments Group first reported a position in SYRS in Q3 2017 and held it in 21 quarters. The position peaked at $331K in Q1 2021. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • Russell Investments Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Russell Investments Group sold 750 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.61K.
  • Russell Investments Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 21 quarters.
  • Russell Investments Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $331K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Russell Investments Group's 13F filing for Q4 2024, filed 13 Feb 2025.